|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 1 August 2005, Vol. 106, No. 3, pp. 929-931. Prepublished online as a Blood First Edition Paper on April 21, 2005; DOI 10.1182/blood-2004-12-4955.
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY PF4/heparin complexes are T cell–dependent antigensFrom the Divisions of Hematology and Cardiology, Duke University Medical Center, Durham, NC; Department of Pediatrics, Children's Hospital of Philadelphia, PA; Department of Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia; and Cardeza Foundation for Hematologic Research, Jefferson Medical College, Philadelphia, PA.
Heparin-induced thrombocytopenia (HIT) is a life-threatening, thrombotic disorder associated with development of anti–platelet factor 4 (anti-PF4)/heparin autoantibodies. Little is known about the antigenic and cellular requirements that initiate the immune response to these complexes. To begin to delineate mechanisms of autoantibody formation in HIT, we studied the immunizing effects of murine PF4 (mPF4)/heparin in mice with and without thymic function. Euthymic mice were injected with mPF4/heparin complexes, mPF4, heparin, or buffer. Mice injected with mPF4/heparin, but not mPF4 or heparin alone, developed heparin-dependent autoantibodies that shared serologic and functional characteristics of human HIT antibodies, including preferential binding to mPF4/heparin complexes and causing heparin- and FcR  IIA-dependent platelet activation. In contrast, athymic mice did not develop HIT-like antibodies. Taken together, these studies establish that PF4/heparin complexes are highly immunogenic and elicit self-reacting anti-PF4/heparin antibodies in a T cell–dependent manner.
Heparin-induced thrombocytopenia (HIT) is a commonly acquired immune disorder caused by autoantibodies to complexes between platelet factor 4 (PF4) and heparin. We have previously shown in a mouse model that passive infusion of PF4/heparin antibodies into transgenic mice expressing human PF4 and Fc RIIA triggers the salient features of the human disease, thrombocytopenia and thrombosis.1 However, little is known about the initiation of the HIT immune response. In particular, the role of T cells in this disorder remains to be defined, because HIT has characteristics of both T cell–dependent (TD) and T cell–independent (TI) responses. On the one hand, serologic studies consistently demonstrate the importance of isotype switching,2 a process that often requires CD4 T-cell help, and clonal restriction in the T-cell repertoire of patients with HIT has been reported.3,4 On the other hand, HIT has features that are atypical for a TD immune disorder. Whereas TD drug reactions to drugs like penicillin or sulfonamides5,6 are typically long-lived and associated with immunologic memory, antibodies to PF4/heparin appear to be transient7 and recurrences do not invariably follow heparin reexposure, suggesting the absence of immunologic memory in HIT.7,8 These observations, in addition to the extraordinary prevalence of PF4/heparin antibody formation in clinical settings such as cardiopulmonary bypass,9 cast doubt on the requirement for T-cell help in the generation of anti-PF4/heparin antibodies. Therefore, to begin to delineate the relevant antigenic and cellular mechanisms that lead to PF4/heparin antibody production in vivo, we studied the sensitizing effects of PF4 and heparin in mice that have or lack thymic function. Our studies indicate that heparin is antigenic only in the presence of PF4 and that PF4/heparin antibody production in vivo is dependent on thymic function.
Murine immunization model Eight- to 10-week-old mice (BALB/c, Jackson Laboratory, Bar Harbor, ME; and BIG:BALB/c-Nu, Cancer Research Isolation Facility, Duke University Medical Center, Durham, NC) were immunized intravenously daily for 5 days via the tail vein or using retro-orbital injection. Sterile solutions containing murine (m) PF4 (20 µg per mouse) and/or heparin (0.4 units per mouse, Heplock; Elkins-Sinn, Cherry Hill, NJ) or dinitrophenol (DNP)–Ficoll (50 µg per mouse; Biosearch Technologies, Novato, CA) were prepared in Hanks balanced salt solution in a final volume of 50 µL. Blood for enzyme-linked immunosorbent assay (ELISA) was collected from the retro-orbital plexus of anesthetized mice in 3.2% sodium citrate. All studies were performed with the approval of the Institutional Animal Care & Use Committee at Duke University. mPF4 expression, mPF4/heparin ELISA, and assays of platelet activation mPF4 was expressed and isolated from an Escherichia coli expression vector as previously described.10 Isolated mPF4 protein ran as a single band at a molecular weight (Mw) of about 7 to 8 kDa and was immunoreactive with a polyclonal anti–human PF4 (hPF4) antibody developed in our laboratory (data not shown). Isolated protein was used for injections as well as for developing an mPF4/heparin ELISA using protocols similar to that described by us for anti–human PF4/heparin.11 Flow cytometry to detect heparin-dependent platelet activation was performed as previously described.12
Statistical analysis Antibody responses were compared using the Student t test for comparisons of 2 groups or analysis of variance (ANOVA) for 3 or more groups. Statistical analyses were performed using Graph Pad Prism (Graphpad Software, San Diego, CA). Differences were considered significant at P less than .05.
These studies were undertaken to examine the mechanism underlying autoantibody formation in HIT. Mice injected with intravenous mPF4/heparin developed significantly higher levels of anti-mPF4/heparin antibody than mice injected with heparin alone, mPF4 alone, or buffer (Figure 1A; mean A450nm ± SD: mPF4/heparin, 0.174 ± 0.336; mPF4, 0.008 ± 0.015; heparin, 0.022 ± 0.009; and buffer, 0.015 ± 0.009; P < .022 by ANOVA with Kruskal-Wallis test). These findings support the hypothesis that heparin becomes antigenic only upon binding to PF4 and suggest that it is reasonable to attribute sensitization to heparin to the formation of PF4/heparin complexes. In humans, sensitization to PF4 may begin within the vasculature. PF4, released by activated platelets,13 binds reversibly to glycosaminoglycans (GAGs) expressed on endothelial cells14 and is displaced by infused heparin.15 There is a 15- to 300-fold increase in the plasma concentration of PF4 in disease states associated with acute or chronic platelet activation, such as pulmonary embolism, atherosclerosis, or cardiopulmonary bypass.16-18 We recently showed that the vascular burden of PF4 increases during the progression of atherosclerosis,19 a clinical setting in which PF4/heparin autoantibodies commonly develop. Further, the knowledge that PF4 forms antigenic complexes with GAGs on monocyte/macrophages20,21 suggests that similar events are likely to occur on dendritic cells within the immune compartment, thus "priming" the immune system in susceptible individuals. We suspect that the absence of vascular disease or other causes of persistent platelet activation in mice, which primes the immune response in humans, explains both the requirement for exogenous mPF4 and for the delay in antibody formation. Although mice immunized with mPF4/heparin develop antibodies within 14 days, peak responses were not seen until 3 to 4 weeks after immunization (Figure 1B). Antibody titers (concentrations) in our mice varied considerably, similar to human HIT (Figure 1B). The basis for this heterogeneity in antibody development is unknown but is likely due to genetic variation that may resolve when more homogenous cohorts are developed following extensive backcrossing.
We also observed that murine anti-PF4/heparin antibodies shared important serologic and functional characteristics with HIT autoantibodies. First, murine anti-PF4/heparin antibodies were predominantly of the immunoglobulin G1(IgG1) subclass (data not shown), as are HIT antibodies.22,23 Second, murine antibodies showed greater binding to mPF4/heparin than to mPF4 alone, and binding was inhibited by excess heparin (Figure 1C). Third, murine antibodies activated platelets in a heparin-dependent manner (Figure 1D). Fourth, like HIT antibodies,24 platelet activation by murine antibodies was dependent on the expression of platelet Fc Once we demonstrated that murine anti-PF4/heparin shared biologically relevant properties with HIT antibodies, we examined the cellular requirements for antibody production in vivo. To investigate the role of T cells in the immune response to PF4/heparin, we immunized mice lacking thymic function (nu/nu mice) with mPF4/heparin (n = 23) or DNP-Ficoll (n = 5), a TI antigen. Antibody responses in athymic mice injected with mPF4/heparin were negligible compared with WT BALB/c mice injected using the same protocol whether assayed at 14 days (Figure 2A; mean A450nm ± SD: nu/nu, 0.003 ± 0.025; versus WT, 0.175 ± 0.459; P < .003 by Mann-Whitney) or 42 days (Figure 2B; A450nm ± SD: nu/nu, 0.02 ± 0.023; versus WT, 0.262 ± 0.303; P < .001 by Mann-Whitney). This contrasts with the immune response of athymic and WT mice injected with DNP-Ficoll, wherein antibody responses were comparable (Figure 2A; meanA450nm ± SD: nu/nu, 0.589 ± 0.173; versus WT, 0.694 ± 0.146; P = not significant [ns]).
In conclusion, our murine studies indicate that PF4/heparin complexes are immunogenic in vivo in contrast to PF4 or heparin alone. These autoantibodies have similar characteristics to HIT antibodies. Most importantly, we show in our murine system that the production of these anti-PF4/heparin antibodies requires T cells that have been educated in the thymus. This mouse model of autoantibody production will enable future studies to delineate the immunoregulatory and pathogenic mechanisms involved in the development of HIT.
Submitted January 3, 2005; accepted March 25, 2005.
Prepublished online as Blood First Edition Paper, April 21, 2005; DOI 10.1182/blood-2004-12-4955.
Supported by American Heart Association (AHA 0465366U [G.A.]), Pfeiffer Foundation (G.A.), and National Institutes of Health grants T32-HL007057 (S.S.), HL04245 (B.S.S.), HL54500 and HL54749 (M.P., D.B.C.), and HL69471 (M.P.R., S.E.M., D.B.C.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Gowthami Arepally, Division of Hematology, DUMC Box 3486, Rm 301 Alex H. Sands Bldg, Research Dr, Durham, NC 27710; e-mail: arepa001{at}mc.duke.edu.
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
